Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

cenersen

cenersen with standard of care

DRUG

Idarubicin

standard of care for AML

DRUG

Cytarabine

standard of care Ara-C and High dose Ara-C

Trial Locations (6)

11041

North Shore University Hospital, Lake Success

14263

Roswell Park Cancer Institute, Buffalo

33136

University of Miami Health Center, Miami

63110

Washington University Medical Center (Siteman Cancer Center), St Louis

77030

M. D. Anderson Cancer Center, Houston

92093-0960

University of California, San Diego, La Jolla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Eleos, Inc.

INDUSTRY

NCT00074737 - Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | Biotech Hunter | Biotech Hunter